Anti-Human NT-3 (Clone41512)

Purified Recombinant Human NT-3 (Accession # P20783)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Human NT-3 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human NT-3 (at 100 ng/ml) is 0.1 - 0.5 µg/ml.

Mouse Anti-Human Neurotrophin 3 (NT-3) (Clone 41512) recognizes an epitope on Human NT-3. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Neurotrophin 3 (NT-3), also known as NTF3 is a basic protein found in neurons of the central nervous system. NT-3 selectively supports the survival of neuronal cell populations. It rapidly potentiate the spontaneous and impulse-evoked synaptic activity of developing neuromuscular synapses in culture and thus appears to be involved in the regulation of functions of developing synapses.^1,2,3 NT-3 negatively modulates nerve growth factor (NGF) receptor expression and associated nociceptive phenotype in intact neurons, suggesting a beneficial role in treating aspects of neuropathic pain mediated by NGF. NT-3 is effective at suppressing thermal hyperalgesia associated with chronic constriction injury (CCI).⁴

1. Barde, YA. et al. (1990) Progress in Growth Factor Res. 2: 237
2. Thoenen, H. et al. (1991) Trends in Neurological Scienc. 14: 165
3. Vantini, G. et al. (1992) Psychoneuroendocrinology 17: 401
4. Verge, VM. et al. (2005) J Neurosci. 25(3):758-67